About MaaT Pharma
MaaT Pharma is a company based in Lyon (France) founded in 2014. MaaT Pharma has raised $42.3 million across 14 funding rounds from investors including Bpifrance, European Union and Symbiosis. MaaT Pharma offers products and services including MaaT013, MET-N, MET-C, gutPrint®, and MaaT033. MaaT Pharma operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Lyon, France
- Stage Public
- SectorsHealthcare
- Website maatpharma.com
- Social LinkedIn X YouTube
- Legal Name Maat Pharma
- Annual Revenue$5.31 M (USD)40.67as on Dec 31, 2025
- Net Profit-$36.5 M (USD)-7.46as on Dec 31, 2025
- EBITDA-$38.08 M (USD)-6.05as on Dec 31, 2025
- Total Equity Funding$42.3M (USD)
in 14 rounds
- Latest Funding Round$2.24M (USD), Grant
Jul 2021
- InvestorsBpifrance
& 10 more
Products & Services of MaaT Pharma
MaaT Pharma offers a comprehensive portfolio of products and services, including MaaT013, MET-N, MET-C, gutPrint®, and MaaT033.
Phase 3 therapy for improving cancer patient survival rates.
Microbiome ecosystem treatment for oncology applications.
Gut-focused therapy for cancer-related immune modulation.
Platform for analyzing microbiome in cancer contexts.
Phase 2b treatment for patients undergoing allo-HSCT.
Apps and channels of MaaT Pharma
its YouTube channel MaaT Pharma has 62 subscribers and 11 videos.
Videos from MaaT Pharma
The most watched videos on MaaT Pharma's YouTube channel, MaaT Pharma (62 subscribers). Click a video to play it here.
More on MaaT Pharma.
Funding Insights of MaaT Pharma
MaaT Pharma has successfully raised a total of $42.3M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $2.24 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.3M
- Total Rounds 14
- Last Round Grant — $2.24M
- First Round $1.25M
(Dec 2014)
- Investors Count 11
Latest 10 of 14 funding rounds of MaaT Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $2.24M | Grant | – | – | – |
| Dec 2020 | $8.79M | Series B | – | Bpifrance | |
| Sep 2020 | $147,001 | Grant | – | – | |
| Feb 2020 | $19.89M | Series B | – | Symbiosis | |
| Jan 2020 | $147,001 | Grant | – | – | |
| Nov 2016 | $449,171 | Grant | – | – | |
| Mar 2016 | $11.26M | Series A | – | Credit Mutuel Equity | |
| Jan 2016 | $449,171 | Grant | – | – | |
| Jul 2015 | $1.1M | Seed | – | – | |
| Jun 2015 | $90,680 | Grant | – | – |
11 investors in total: 11 institutional.
Investors in MaaT Pharma
MaaT Pharma has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, European Union and Symbiosis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are directed toward life science sectors. | – | skyviewslifescience.com | - | |
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | – | seventure.fr | Paris, France | |
Growth and acquisition investments are managed by Credit Mutuel Equity. | – | creditmutuel-equity.eu | Paris, France | |
A Single Family Office based in Geneva, Switzerland. | – | celeste-management.eu | Geneva, Switzerland | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
Business services for the healthcare sector are provided by Symbiosis. | 2017 | joinsymbiosis.com | - | |
Crédit Mutuel is recognized as a cooperative banking institution. | – | creditmutuel.fr | Strasbourg, France | |
Biocodex is recognized as a multinational pharmaceutical company. | – | biocodex.com.tr | France | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
- | – | inra-transfert.fr | - |
Investor details for MaaT Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of MaaT Pharma
MaaT Pharma is a publicly listed company on the EURONEXT with ticker symbol MAAT in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Nov 2021
- Listed onEuronext: MAAT
- Listed entityMaaT Pharma
- Exchange sectorHealth technology
- ISINFR0012634822
- Share price0.92 EUR (-0.97% on the day) · 2026-10-09
- Market capitalisation17,536,445.00 EUR
- EPS (diluted, trailing year)-1.92 EUR
- Volume (last session)7,499
Financials of MaaT Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.5M EUR | -31.1M EUR | -32.4M EUR |
| 2024 | 3.2M EUR | -28.9M EUR | -30.6M EUR |
| 2023 | 2.2M EUR | -19.7M EUR | -23.7M EUR |
| 2022 | 1.4M EUR | -13.7M EUR | -17.2M EUR |
| 2021 | 972,000 EUR | -9.0M EUR | -11.0M EUR |
Detailed financial statements for MaaT Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of MaaT Pharma
4 dated milestones of MaaT Pharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded MaaT Pharma is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Grant, of $2.2M.
- IPO Lists on the stock exchange (IPO).
Competitors of MaaT Pharma
MaaT Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| novozymes.com | 2000 | Bagsvaerd, Denmark | – | 6,781 | Biosolutions and enzymes are developed for biotechnology applications across industries. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of MaaT Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MaaT Pharma
The website of MaaT Pharma (maatpharma.com) receives about 7.3K visits a month.
- Monthly visits7.3K
▼ 6.6% vs previous month
Latest news on Maat Pharma
Complete news archive for MaaT Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to MaaT Pharma
10 companies that operate in the same segment as MaaT Pharma (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MaaT Pharma
MaaT Pharma was founded in 2014.
MaaT Pharma is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
MaaT Pharma is a funded company, having raised a total of $42.3M across 14 funding rounds to date. The company's 1st funding round was a Grant of $90.68K, raised on Dec 2014.
Annual revenue of MaaT Pharma is $5.31M as on Dec 31, 2025.
MaaT Pharma was established in 2014 in Lyon, France, within the biotech sector. Microbiome-based treatments are created for addressing intestinal dysbiosis in patients with malignant blood diseases or bone infections. Autologous intestinal microbiota transplants are employed as the primary method. Heavy therapies that induce dysbiosis are countered through these interventions. Operations center on therapeutic development for such conditions, with a focus on clinical applications.
MaaT Pharma's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
MaaT Pharma offers MaaT013, MET-N, MET-C, gutPrint®, and MaaT033.
Yes, MaaT Pharma is publicly traded on EURONEXT under the ticker symbol MAAT.
MaaT Pharma has 11 investors. Key investors include Bpifrance, European Union, Symbiosis, Celeste Management, and Skyviews Life Science.